Loading
NASDAQHealthcareBiotechnology
Latest quote
$19.9513
−$0.6087 · -2.96%
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Regular session
$19.9513
−$0.6087 · -2.96%
Regular session · ET · Market data may be delayed.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Day range
Current $19.9513
52-week range
Current $19.9513
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
49
Mixed
Risk
52
Elevated Risk
Momentum
69
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Day range
Current $19.9513
52-week range
Current $19.9513
Third-party consensus; not a GoAI recommendation.
Average target
$20.50
2.75% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR116.88M0.11%104.29B USD0.06%$137.05-0.03%
Vanguard Morningstar Total Stock Market ETFVTI55.03M0.00%2.3T USD0.03%$379.01-0.53%
iShares Russell 2000 ETFIWM52.08M0.07%78.56B USD0.19%$277.17-0.19%
Vanguard Extended Market ETFVXF20.15M0.02%95.4B USD0.05%$232.88-0.26%
Vanguard Morningstar Small-Cap ETFVB19.97M0.01%185.3B USD0.03%$287.22+0.08%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM18.22M0.11%16.01B USD0.03%$53.275-0.01%
Invesco S&P SmallCap Momentum ETFXSMO17.21M0.60%2.92B USD0.35%$81.44-0.56%
Schwab Fundamental U.S. Small Company Index ETFFNDA16.45M0.19%8.72B USD0.25%$35.495+0.27%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMInvesco S&P SmallCap Momentum ETFXSMOSchwab Fundamental U.S. Small Company Index ETFFNDAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
